Merck KGaA study finds variation in NSCLC treatment
There are striking differences in treatment regimens for non-small cell lung cancer patients, based on both age and geography, according to a new market research study presented by Germany's Merck KGaA at the American Society of Clinical Oncology meeting in Orlando, Florida.
Performed in conjunction with TNS Healthcare, the representative study shows that, among patients with advanced NSCLC, monotherapy is used most often among those 70 or older, while combination therapies are administered most frequently to younger patients. Location also is a key factor in determining therapy choice, with a chemotherapy doublet plus a targeted agent far more common in the USA than in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze